• Publications
  • Influence
Recent advances in the biology of heavy-ion cancer therapy.
This paper briefly reviews the current knowledge of the biological aspects of heavy-ion therapy, and focuses on the authors' recent findings on repair mechanisms of heavy ion-induced DNA damage. Expand
Induction of DNA double-strand breaks and cellular migration through bystander effects in cells irradiated with the slit-type microplanar beam of the spring-8 synchrotron.
Bystander effects are produced by factors secreted as a result of slit-type microplanar X-ray beam irradiation, suggesting that DNA dsbs were induced in nonirradiated cells by soluble factors in the culture medium. Expand
Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer
This study confirmed the feasibility of the dose-estimation method and that controlled trials are warranted and that the dose constraint was set to deliver a dose <10–12 Gy-eq to the skin or oral mucosa. Expand
Local hyperthermia combined with external irradiation for regional recurrent breast carcinoma
A significant benefit of local hyperthermia combined with radiotherapy in the treatment of locally recurrent breast cancer, especially for previously irradiated recurrence, is suggested by reducing the total irradiation dose. Expand
Effective suppression of bystander effects by DMSO treatment of irradiated CHO cells.
The results suggest that the prevention of oxidative stress is independent of the suppressive effect of DMSO on the formation of the bystander signal in irradiated cells, and it is suggested that increased ROS in irradiate cells is not a substantial trigger of a bystanderser signal. Expand
Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.
The data suggested that BPA distributed in tumors hetergeneously, especially Q cells especially might not accumulate BPA, and the combination of BPA and BSH or other neutron capture element that emit particles with longer ranges, for example, gadolinium, would have to be investigated. Expand
Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron capture therapy
Abstract At Kyoto University Research Reactor Institute (KURRI), 275 clinical trials of boron neutron capture therapy (BNCT) have been performed as of March 2006, and the effectiveness of BNCT hasExpand
Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control.
Results indicate that OTT is a significant prognostic factor for local control of T1 glottic tumors, and dose and fraction size were not significant. Expand
Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on
This modified BNCT produced a good improvement in malignant gliomas, as seen on neuroimages, and more than 50% of the contrast-enhanced lesions disappeared in eight of the 12 patients during the follow-up period. Expand
First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma.
The feasibility of BNCT for HCC is confirmed in this first case and the patient died of liver dysfunction caused by progression of HCC 10 months after BnCT. Expand